The producer of a generally used abortion capsule requested the Supreme Court on Friday to listen to a problem to the provision of the drug, mifepristone, elevating the chance that the justices will rule on the destiny of entry to the medicine.

The transfer units up a showdown over the capsule, which is utilized in greater than half of all abortions within the United States, and would convey abortion again to the courtroom greater than a yr after the justices eliminated the constitutional right to abortion. The case might even have implications for the pharmaceutical trade, together with the Food and Drug Administration’s regulatory authority over different drugs.

In its request, Danco Laboratories known as the case considered one of “indisputable importance” and outlined the wide-ranging reverberations of any resolution.

“For the women and teenage girls, health care providers, and states that depend on F.D.A.’s actions to ensure safe and effective reproductive health care is available, this case matters tremendously,” the corporate wrote. “And for the pharmaceutical and biotechnology industry, permitting judicial second-guessing of F.D.A.’s scientific evaluations of data will have a wildly destabilizing effect.”

The request got here in response to a ruling by a federal appeals courtroom final month that upheld the legality of the capsule however imposed important restrictions on its distribution. The ruling by a three-judge panel would forestall the drug from being despatched by mail or prescribed by telemedicine.

For now, the capsule stays accessible as a result of the Supreme Court determined in April that entry to the drug would stay unchanged till the appeals course of completed.

The courtroom, which is prone to act within the coming months, might decline to listen to the case, leaving the decrease courtroom’s resolution in place. Or it might agree to listen to the case.

The firm added that the case sought to restrict entry to abortion fairly than decide the protection of a drug authorised greater than twenty years in the past. The firm argued that the decrease courtroom had moved to restrict entry to the drug “at the request of a group of plaintiffs who do not prescribe or use the drug and whose real disagreement with F.D.A. is that they oppose all forms of abortion.”

The case arose from a lawsuit filed in federal courtroom in Amarillo, Texas, months after the Supreme Court overturned Roe v. Wade in June 2022. The plaintiffs, a coalition of 4 docs and a bunch against abortion, requested a federal choose to overturn the F.D.A.’s approval of the drug greater than twenty years earlier than. The capsule is the primary in a two-drug routine for terminating a being pregnant.

In March, Judge Matthew J. Kacsmaryk of the Northern District of Texas, a Trump appointee identified for his anti-abortion views, issued a preliminary ruling that stated the F.D.A.’s approval of the drug ought to be suspended, eradicating mifepristone from the market.

The Biden administration requested the Supreme Court to intervene, and the courtroom ordered that mifepristone would stay broadly accessible till the appeals course of concluded.

Pam Belluck contributed reporting.